Storm Therapeutics Secures $56 Million Series C to Push METTL3 Cancer Drug Into Phase 2

Why It Matters

The Series C round validates a new therapeutic modality—epitranscriptomic inhibition—by attracting heavyweight pharma investors. If Storm’s METTL3 inhibitor demonstrates clinical benefit, it could unlock a class of drugs for cancers that have resisted conventional targeted therapies, reshaping treatment paradigms for sarcomas and potentially other malignancies. Moreover, the financing signals a broader re‑allocation of capital toward high‑risk, high‑reward science, suggesting that the biotech funding environment is once again rewarding innovative biology over incremental advances. Beyond Storm, the deal may accelerate collaborations between biotech firms and large pharma, as venture arms seek to de‑risk early‑stage RNA‑modifying programs. Successful outcomes could spur a wave of similar investments, expanding the pipeline of RNA‑focused therapeutics and prompting regulatory agencies to refine pathways for these novel mechanisms.

Key Takeaways

• Storm Therapeutics raised $56 million in a Series C round led by Pfizer Ventures and M Ventures.
• Funding will launch a Phase 2 monotherapy trial of STC‑15, a first‑in‑class METTL3 inhibitor, in sarcomas.
• STC‑15 showed durable tumor regression in Phase 1 across multiple sarcoma subtypes.
• The investor syndicate includes Taiho Ventures, IP Group, UTokyo Innovation Platform and Fast Track Initiative.
• First patient dosed; trial designed for accelerated approval, with data expected in late 2027.

Pulse Analysis

Storm Therapeutics’ $56 million raise is more than a cash infusion; it is a market endorsement of epitranscriptomics as a viable drug discovery axis. Historically, RNA‑targeted therapies have struggled to move beyond antisense and siRNA modalities, largely because the enzymatic machinery that writes and erases RNA marks was considered intractable. Storm’s METTL3 inhibitor flips that narrative, offering a small‑molecule approach that can be administered orally and combined with existing regimens.

The involvement of Pfizer Ventures and M Ventures is particularly telling. Both firms have recently doubled down on platforms that promise to address unmet oncology needs, and their participation suggests that large pharma sees a strategic advantage in owning early rights to epitranscriptomic assets. This could accelerate licensing deals or co‑development agreements, mirroring the path taken by DNA‑damage response inhibitors a few years ago. If Storm’s Phase 2 data confirm the durability observed in Phase 1, we may witness a cascade of partnership announcements, as larger companies scramble to integrate METTL3 inhibition into their oncology portfolios.

From a market perspective, Storm’s progress could recalibrate valuation models for RNA‑modifying biotech firms. Investors have been cautious after a wave of high‑profile failures in RNA‑targeted oncology, but a successful readout would restore confidence and likely trigger a new funding round at higher multiples. In the broader biotech ecosystem, the Storm story may encourage other startups to explore less‑traveled enzymatic targets, expanding the therapeutic landscape beyond the current focus on surface receptors and DNA mutations. The next 12‑18 months will be pivotal: positive Phase 2 outcomes could cement epitranscriptomics as a cornerstone of precision oncology, while a setback would reinforce the challenges of translating novel biology into patient benefit.